Margaretha G.M. Roemer

PURPOSE: Classical Hodgkin lymphomas (cHLs) include small numbers of malignant Reed-Sternberg cells within an extensive but ineffective inflammatory/immune cell infiltrate. In cHL, chromosome 9p24.1/PD-L1/PD-L2 alterations increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and their further induction through Janus kinase 2-signal transducers and activators of transcription signaling. The unique composition of cHL limits its analysis with high-throughput genomic assays. Therefore, the precise incidence, nature, and prognostic significance of PD-L1/PD-L2 alterations in cHL remain undefined. METHODS: We used a fluorescent in situ hybridization assay to evaluate CD274/PD-L1 and PDCD1LG2/PD-L2 alterations in 108 biopsy specimens from patients with newly diagnosed cHL who were treated with the Stanford V regimen and had long-term follow-up. In each case, the frequency and magnitude of 9p24.1 alterations-polysomy, copy gain, and amplification-were determined, and the expression of PD-L1 and PD-L2 was evaluated by immunohistochemistry. We also assessed the association of 9p24.1 alterations with clinical parameters, which included stage (early stage I/II favorable risk, early stage unfavorable risk, advanced stage [AS] III/IV) and progression-free survival (PFS). RESULTS: Ninety-seven percent of all evaluated cHLs had concordant alterations of the PD-L1 and PD-L2 loci (polysomy, 5% [five of 108]; copy gain, 56% [61 of 108]; amplification, 36% [39 of 108]). There was an association between PD-L1 protein expression and relative genetic alterations in this series. PFS was significantly shorter for patients with 9p24.1 amplification, and the incidence of 9p24.1 amplification was increased in patients with AS cHL. CONCLUSION: PD-L1/PD-L2 alterations are a defining feature of cHL. Amplification of 9p24.1 is more common in patients with AS disease and associated with shorter PFS in this series. Further analyses of 9p24.1 alterations in patients treated with standard cHL induction regimens or checkpoint blockade are warranted.

Abstract In classical Hodgkin lymphoma (cHL), malignant Hodgkin Reed–Sternberg (HRS) cells evade antitumor immunity by multiple mechanisms, including perturbed antigen presentation and enhanced PD-1 signaling. HRS cell expression of the PD-1 ligands is attributable, in part, to copy number alterations of 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2). Amplification of PD-L1/PD-L2 is associated with advanced clinical stage and inferior progression-free survival (PFS) following first-line (induction) therapy. The relationships between altered expression of β2-microglobulin (β2M), MHC class I, and MHC class II by HRS cells, PD-L1/PD-L2 amplification, and clinical outcome in cHL are poorly defined. We assessed these variables in diagnostic biopsy specimens from 108 patients with cHL who received uniform treatment and had long-term follow-up and found decreased/absent expression of β2M/MHC class I in 79% (85/108) and decreased/absent expression of MHC class II in 67% (72/108) of cases. Patients with decreased/absent β2M/MHC class I had shorter PFS, independent of PD-L1/PD-L2 amplification and advanced stage. Decreased or absent MHC class II was unrelated to outcome. These results suggest that MHC class I–mediated antigen presentation by HRS cells is an important component of the biological response to standard chemo/radiotherapy. The paucity of β2M/MHC class I expression on HRS cells also prompts speculation regarding alternative mechanisms of action of PD-1 blockade in cHL. Cancer Immunol Res; 4(11); 910–6. ©2016 AACR.

PD-1/PD-L1 immune checkpoint inhibitors show potential for cervical cancer treatment. However, low response rates suggest that patient selection based on PD-L1 protein expression is not optimal. Here, we evaluated different PD-L1 detection methods and studied transcriptional regulation of PD-L1/PD-L2 expression by The Cancer Genome Atlas (TCGA) mRNAseq analysis. First, we determined the copy number of the PD-L1/PD-L2 locus by fluorescence in situ hybridization (FISH), PD-L1 mRNA expression by RNA in situ hybridization (RNAish), and PD-L1/PD-L2 protein expression by immunohistochemistry (IHC) on tissue microarrays containing a cohort of 60 patients. Additionally, distribution of PD-L1/PD-L2 was visualized based on flow cytometry analysis of single-cell suspensions (n = 10). PD-L1/PD-L2 locus amplification was rare (2%). PD-L1 mRNA expression in tumor cells was detected in 56% of cases, while 41% expressed PD-L1 protein. Discordant scores for PD-L1 protein expression on tumor cells between cores from one patient were observed in 27% of cases. Interestingly, with RNAish, PD-L1 heterogeneity was observed in only 11% of the cases. PD-L2 protein expression was found in 53%. PD-L1 mRNA and protein expression on tumor cells were strongly correlated (p < 0.001). PD-L1 and PD-L2 protein expression showed no correlation on tumor cells (p = 0.837), but a strong correlation on cells in stromal fields (p < 0.001). Co-expression of PD-L1 and PD-L2 on macrophage-like populations was also observed with flow cytometry analysis. Both PD-L1 and PD-L2 TCGA transcript levels strongly correlated in the TCGA data, and both PD-L1 and PD-L2 strongly correlated with interferon gamma (IFNG) expression/transcript levels (p < 0.0001). Importantly, patients with high PD-L1/PD-L2/IFNG transcript levels had a survival advantage over patients with high PD-L1/PD-L2 and low IFNG expression. Based on these findings, we conclude that PD-L1/PD-L2 expression in cervical cancer is mainly associated with interferon induction and not gene amplification, which makes FISH unsuitable as biomarker. The heterogeneous PD-L1 and PD-L2 expression patterns suggest IHC unreliable for patient selection. RNAish, in conjunction with interferon signaling evaluation, seems a promising technique for immune checkpoint detection. These results warrant further investigation into their prognostic and predictive potential.

tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed/refractory (RR) B-NHL patients. In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent activity against primary tumor cells, irrespective of prior treatments, including CD20 mAbs. Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. Furthermore, in this allogeneic setting, we discovered that the capacity of B-cell tumors to activate T-cells was heterogeneous and showed an inverse association with their surface expression levels of the immune checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous setting, when lymph node (LN)-residing T-cells were the only source of effector cells, the epcoritamab-dependent cytotoxicity strongly correlated with local effector cell-to-target cell ratios. Further analyses revealed that LN-residing-derived or peripheral blood-derived T-cells of B-NHL patients, as well as heathy donor T-cells equally mediated epcoritamab-dependent cytotoxicity. These results show the promise of epcoritamab for treatment of newly-diagnosed or relapsed/refractory B-NHL patients, including those who became refractory to previous CD20-directed therapies.

Whole genome sequencing (WGS) using fresh-frozen tissue and matched blood samples from cancer patients may become the most complete genetic tumor test. With the increasing availability of small biopsies and the need to screen more number of biomarkers, the use of a single all-inclusive test is preferable over multiple consecutive assays. To meet high-quality diagnostics standards, we optimized and clinically validated WGS sample and data processing procedures, resulting in a technical success rate of 95.6% for fresh-frozen samples with sufficient (≥20%) tumor content. Independent validation of identified biomarkers against commonly used diagnostic assays showed a high sensitivity (recall; 98.5%) and precision (positive predictive value; 97.8%) for detection of somatic single-nucleotide variants and insertions and deletions (across 22 genes), and high concordance for detection of gene amplification (97.0%; EGFR and MET) as well as somatic complete loss (100%; CDKN2A/p16). Gene fusion analysis showed a concordance of 91.3% between DNA-based WGS and an orthogonal RNA-based gene fusion assay. Microsatellite (in)stability assessment showed a sensitivity of 100% with a precision of 94%, and virus detection (human papillomavirus), an accuracy of 100% compared with standard testing. In conclusion, whole genome sequencing has a >95% sensitivity and precision compared with routinely used DNA techniques in diagnostics, and all relevant mutation types can be detected reliably in a single assay. Whole genome sequencing (WGS) using fresh-frozen tissue and matched blood samples from cancer patients may become the most complete genetic tumor test. With the increasing availability of small biopsies and the need to screen more number of biomarkers, the use of a single all-inclusive test is preferable over multiple consecutive assays. To meet high-quality diagnostics standards, we optimized and clinically validated WGS sample and data processing procedures, resulting in a technical success rate of 95.6% for fresh-frozen samples with sufficient (≥20%) tumor content. Independent validation of identified biomarkers against commonly used diagnostic assays showed a high sensitivity (recall; 98.5%) and precision (positive predictive value; 97.8%) for detection of somatic single-nucleotide variants and insertions and deletions (across 22 genes), and high concordance for detection of gene amplification (97.0%; EGFR and MET) as well as somatic complete loss (100%; CDKN2A/p16). Gene fusion analysis showed a concordance of 91.3% between DNA-based WGS and an orthogonal RNA-based gene fusion assay. Microsatellite (in)stability assessment showed a sensitivity of 100% with a precision of 94%, and virus detection (human papillomavirus), an accuracy of 100% compared with standard testing. In conclusion, whole genome sequencing has a >95% sensitivity and precision compared with routinely used DNA techniques in diagnostics, and all relevant mutation types can be detected reliably in a single assay. Needs and complexity in molecular cancer diagnostics are rapidly increasing, driven by a growing number of targeted drugs and developments toward more personalized treatments.1Hyman D.M. Taylor B.S. Baselga J. Implementing genome-driven oncology.Cell. 2017; 168: 584-599Abstract Full Text Full Text PDF PubMed Scopus (250) Google Scholar,2Mosele F. Remon J. Mateo J. Westphalen C.B. Barlesi F. Lolkema M.P. Normanno N. Scarpa A. Robson M. Meric-Bernstam F. Wagle N. Stenzinger A. Bonastre J. Bayle A. Michiels S. Bièche I. Rouleau E. Jezdic S. Douillard J.-Y. Reis-Filho J. Dienstmann R. André F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.Ann Oncol. 2020; 31: 1491-1505Abstract Full Text Full Text PDF PubMed Scopus (119) Google Scholar Simultaneously, advances in next-generation DNA sequencing technology have greatly enhanced the capability of cancer genome analyses, thereby rapidly progressing diagnostic approaches from small targeted panels to large panels and exome sequencing. Currently, whole genome sequencing (WGS) using tissue and matched blood samples from patients with (metastatic) cancer3Weinstein J.N. Collisson E.A. Mills G.B. Mills Shaw K.R. Ozenberger B.A. Ellrott K. Shmulevich I. Sander C. Stuart J.M. The Cancer Genome Atlas Research NetworkThe Cancer Genome Atlas Pan-Cancer analysis project.Nat Genet. 2013; 45: 1113-1120Crossref PubMed Scopus (3280) Google Scholar is getting in reach as the most complete genetic tumor diagnostics test. In the context of the Dutch national Center for Personalized Cancer Treatment (CPCT) clinical study (NCT01855477; https://clinicaltrials.gov/ct2/show/NCT01855477, last accessed May has a national WGS and in the the for the analysis of tumor biopsies by the in and matched samples have by of the of patients has and J. Lolkema M.P. N. E. C. K. S. A. M. M. S. E. of metastatic PubMed Scopus Google Scholar clinical study to data for with growing clinical for more and DNA analysis for toward targeted R. C. C. and techniques for in clinical Full Text Full Text PDF PubMed Scopus Google Scholar the of WGS is diagnostic of the of tumor tissue for as well as the of the WGS with of more and validation for Currently, is an toward the availability of small for cancer metastatic are using with the a growing need to screen for an increasing number of and molecular diagnostics, the use of a single all-inclusive test is over multiple consecutive assays more more and a complete of the molecular To meet the high-quality diagnostics standards, we have optimized and clinically validated the of the WGS fresh-frozen tumor as well as as are in the precision (positive predictive and sensitivity of the test. The validation biomarkers in tumor genes), of gene and as well as biomarkers, tumor I. for from of somatic PubMed Scopus Google Scholar and S. J. M. S. S. K. E. A. C. A. S. A. S. is a of and 2017; PubMed Scopus Google A. E. of 2020; PubMed Scopus Google Scholar an and and has to the of a and to an of all clinically relevant DNA we WGS has an >95% sensitivity and precision (positive predictive compared with routinely used and all relevant mutation types can be and reliably detected in a single assay. WGS of and can be the tumor a tumor as well as the availability of fresh-frozen tumor for high-quality as WGS has from a technology an for test is to be used for clinical samples used from patients as of the Center for Personalized Cancer Treatment (CPCT) the last accessed May and the Whole genome sequencing in standard for cancer last accessed May clinical by the of the Center and the Cancer patients have to the of data for cancer Whole genome sequencing (WGS) the the The WGS test used DNA from fresh-frozen tumor tissue and from blood samples DNA is the standard and of blood used for DNA using the DNA The DNA used for tissue DNA to DNA by the for DNA amplification the and The and used for sequencing tumor and blood the the sequencing for the tumor and blood samples to be and to be for diagnostic data as tumor and tumor WGS analysis tumor samples with sufficient tumor of tumor samples by tumor of and from the standard used for DNA the of tumor In tumor the WGS data for analysis and of the DNA The sequencing to to be to with a in and with sequencing to for assessment with an of for diagnostics data with an by sequencing techniques a and tumor and of all of the used is in of tumor and blood samples using the variants and insertions and deletions between the tumor using last accessed May with to reliably be S. K. E. M. and of and somatic PubMed Scopus Google Scholar insertions and deletions detected using the last accessed May as is a detection a and a somatic and is to J. R. A. and detection using 2017; PubMed Scopus Google Scholar and gene using the last accessed May of variants in the tumor In with last accessed May and of the tumor and the number and for of the tumor In a using the the from the and in the for WGS to the and number of a tumor sample by for the with the The tumor and be used for detection of loss of J. C. N. E. the tumor genome analysis of and 2020; Scholar tumor for of somatic complete loss of a gene loss of of and deletions of of variants and the and of gene using last accessed May to the the of the and and for J. C. N. E. the tumor genome analysis of and 2020; Scholar the as the number of somatic variants the whole genome of the and the tumor as the number of all somatic variants genome using the by the I. for from of somatic PubMed Scopus Google Scholar In the number of and in of more and of with a as DNA using the A. E. of 2020; PubMed Scopus Google Scholar The is of and to between and The for the of with and the number of large with between and a for with a of and samples as A. E. of 2020; PubMed Scopus Google Scholar the of DNA detected using identified in the genome using a single by of the detected N. E. PubMed Google Scholar and used for analysis of the WGS data are and last accessed The and WGS data used in are for validation and cancer a data last accessed Independent validation for all types of clinically relevant DNA and with gene amplification and as and complete loss of and gene and as WGS compared against as diagnostic assays in a clinical for the validation a test The validation of the used tumor samples and tumor types for validation is as molecular sequencing for of variants detected by The sequencing and to the A. K. A. next-generation sequencing of tissue using single Full Text Full Text PDF PubMed Scopus Google R. M. M. C. A. sequencing high of Genet. 2017; Full Text Full Text PDF PubMed Scopus Google Scholar In to test variants and detected by WGS tumor validation using the DNA as used for and by clinical validation of detection using samples and compared against a next-generation sequencing (NGS) gene in a the Lolkema M.P. DNA-based detection and of in 2020; Full Text Full Text PDF PubMed Scopus Google Scholar The in data of the by Lolkema M.P. DNA-based detection and of in 2020; Full Text Full Text PDF PubMed Scopus Google and using the DNA as used for thereby tumor used for and a clinical report In for a between the assessment and the number assessment validated against in using and a of diagnostic tumor a for the of and and the for the of and and as well as for fusion and fusion a and for for the of with of number validated using tumor samples and using analysis an Center for analysis from the used for WGS from a the to M. M. M. in of of Oncol. PubMed Scopus Google Scholar fresh-frozen using with the used for using the and with clinical report compared with the WGS for the detected by WGS compared with the detected by In to number for samples as for amplification in amplification using the and to the as for of complete loss of by WGS validated using in the WGS data compared against by of tumor using the of gene fusion detection by WGS against RNA-based samples the of the WGS to multiple fusion from the tissue as the DNA used for to clinical report and compared with the WGS a of tumor the validated using the analysis and a A. K. the molecular diagnostics of a for the PubMed Scopus Google Scholar and using the DNA used for assays and tumor and blood samples for the number of as well as of and in the validation and the detection of of virus DNA compared against Cancer using the for and for detection of of in the tumor to standard of for used for with using an of the DNA used for In to the orthogonal clinical validation are in the the of WGS using a sample 100% for all DNA The accuracy of detection and by WGS high and and using multiple a of with a precision of to and a sensitivity of to the precision and of the for detection the for high-quality sequencing data to of all somatic between and a for of the of of resulting in and analysis WGS analysis a of tumor samples and high the genome to The of showed a of to with and of all and for WGS and whole of of samples have in using multiple and a of in from tumor samples used for The in The is a of a accuracy and is from the precision and sensitivity (recall; of the genome in a single-nucleotide whole genome sequencing. in a The samples have in using multiple and a of in from tumor samples used for The in The is a of a accuracy and is from the precision and sensitivity (recall; of the test. genome in a single-nucleotide whole genome sequencing. To the and of the an analysis to the of detected variants for a of tumor J. Lolkema M.P. N. E. C. K. S. A. M. M. S. E. of metastatic PubMed Scopus Google Scholar an of for the WGS used of and are for a sample of a of The tumor for detection using an in sensitivity with a of and of the of the tumor with a sensitivity >95% to reliably a single-nucleotide as tumor using a in in the tumor of and are to be in and all for the tumor the sample showed of the The of the complete diagnostic cancer and an in the with from the DNA samples and in molecular with diagnostic and used for WGS analysis of biopsies from a metastatic WGS of DNA and be from of all To WGS is the tumor a analysis the sample for samples in all of the samples by WGS all with a success rate for and cancer patients DNA can sequencing as for DNA from A. in DNA from and for PubMed Scopus (250) Google Scholar to be for fresh-frozen the DNA is a of sequencing 2017; PubMed Scopus Google Scholar used to The are of DNA to of to with samples a of and samples with resulting in a large of variants to technical DNA is a of sequencing 2017; PubMed Scopus Google Scholar The of samples showed with a of to and samples with a In of the samples showed a of of The Cancer Genome Atlas samples showed a DNA is a of sequencing 2017; PubMed Scopus Google Scholar assessment of a tumor is for of and number as well as assessment and using the fresh-frozen to The and showed a for samples with tumor for samples with tumor of and the tumor all the of a genome to in a in the between and for with tumor of tumor the most rate to of samples showed an between and and showed a of tumor DNA In assessment sequencing data to be used for of biopsies for sequencing. of by and WGS to showed a of with an between of to by an cancer showed sequencing data for and be used as an for samples with sufficient (≥20%) and sufficient DNA the technical success rate for high-quality WGS data and 95.6% of variants detected by WGS by A. K. A. next-generation sequencing of tissue using single Full Text Full Text PDF PubMed Scopus Google R. M. M. C. A. sequencing high of Genet. 2017; Full Text Full Text PDF PubMed Scopus Google Scholar variants and and and by a for of the WGS of the of all of the variants by a high sensitivity of the and a high rate of The showed a high between assays variants be by to a mutation for the the and and clinical validation of in a using samples and compared against the samples showed a mutation by WGS by detected using sequencing identified using single mutation identified by using the WGS analysis of mutation WGS identified variants and by the used variants to in and with a high samples by WGS by sequencing. all somatic the of with the in and detected by of the of by WGS and using sequencing and resulting in an sensitivity and 95.6% precision (positive predictive for WGS compared with mutation identified using the by the WGS test. of the WGS data the of with a in the tumor with a of of with in the blood the somatic from the tumor and and as a somatic be reliably the the report a identified by WGS using the The in the data of The the mutation in a DNA and the sequencing technology used for the sequencing is to more in DNA the as the WGS precision (positive predictive as the of tumor is the of is a of the compared samples between WGS and showed a high by a single high sample of tumor of a concordance for of samples sample by a in the the of using a more gene compared with exome as J.M. S. E. Lolkema of and assessment in metastatic 2020; PubMed Scopus Google J. M. K. E. M. S. S. C. Stenzinger A. tumor Oncol. Full Text Full Text PDF PubMed Scopus Google Scholar orthogonal validation a high sensitivity (recall; 98.5%) and a high precision (positive predictive value; 97.8%) for detection of variants by WGS and 100% and using fresh-frozen biopsies with tumor compared with commonly used approaches K. A. A. of the for next-generation sequencing of clinical PubMed Scopus Google Scholar WGS and number against analysis of of and and and WGS and analysis showed and with in of in in in to and complete and for all validation of amplification detection using samples from tumor types and samples with and amplification WGS as in the J. Lolkema M.P. N. E. C. K. S. A. M. M. S. E. of metastatic PubMed Scopus Google Scholar and is used as in the Dutch for in a and J.M. E. A. M. N. M. E. S. E. The the use of PubMed Scopus Google Scholar fresh-frozen by an sample analysis of tumor by the samples with a WGS number by to between and an by for amplification as for a single number to in of the compared with technical be be of tumor between the used for WGS and a tumor for the is in by WGS and amplification amplification amplification amplification amplification tumor and as to to and to M. M. M. in of of Oncol. PubMed Scopus Google WGS as well as are in whole genome sequencing. in a tumor and as to to and to M. M. M. in of of Oncol. PubMed Scopus Google WGS as well as are in whole genome sequencing. for WGS number detection for using samples as for amplification by in analysis showed with a large from to and a the and data showed a high concordance between WGS and analysis (97.0%; of the WGS reliably detected high gene the concordance showed more the are clinically A. A. A. E. E. Recommendations for the clinical and of number using gene analysis in PubMed Scopus Google Scholar To the detection of complete loss of by the of complete loss of compared with data of samples with of in the tumor as detected by WGS for tumor all for by (100%; 22 of The samples with of to WGS all to be for for samples in the tumor showed complete loss of all to a A. E. of 2020; PubMed Scopus Google Scholar in all of thereby complete of to complete is to reliably by as the are in from the in the tissue the for of the Gene by is for A. E. of 2020; PubMed Scopus Google whole genome sequencing. in a is for A. E. of 2020; PubMed Scopus Google Scholar whole genome sequencing. of gene by WGS compared with with an RNA-based and samples using DNA and from the the of the WGS to more clinically relevant fusion The the WGS for of the samples fusion of and be as the fusion by the used by WGS and the DNA and fusion are in the used next-generation whole genome are in the used assay. in a next-generation whole genome sequencing. fusion detected by 22 be identified using to a multiple in the and more to using WGS data compared with analysis of fusion detected by WGS showed in the tumor fusion DNA a fusion can well be the to are for detection by the assay. WGS (in)stability validated using multiple tumor types and compared with the routinely used A. K. the molecular diagnostics of a for the PubMed Scopus Google M.P. in a PubMed Scopus Google Scholar compared with analysis of by WGS as the number of small in and in and I. for from of somatic PubMed Scopus Google Scholar The of tumor samples showed an of with the of samples a and a toward to of of the samples as using a of the of the the validation the sensitivity of WGS 100% with a precision of and a of In to the the with the number of in samples with showed a of the a sample with a of the as a WGS of as analysis showed loss of WGS analysis a somatic in with a The mutation is with a high in the last accessed and a the test as well as the validated for use in a The a cancer sample with a WGS of a showed a and and by the a validation the sample a with a DNA has the of can be detected with accuracy using M. I. M. A. M. N. R. of in Genet. 2020; PubMed Scopus Google Scholar of detection of the and clinical and the availability of tumor samples used for validation between WGS and and WGS in concordance with standard assessment for all with a of types between for of the samples as using the WGS analysis more a a detection for the and of in WGS and whole genome sequencing. in a whole genome sequencing. In to the orthogonal with of DNA WGS analysis (human number by the with DNA by WGS for the as for the WGS and the data analysis and have from a to a A. F. E. N. M. K. A. validation of clinical and sequencing of for variants in Full Text Full Text PDF PubMed Scopus Google Scholar with the clinical need to screen for an increasing number of biomarkers in an number of tumor types D.M. Taylor B.S. Baselga J. Implementing genome-driven oncology.Cell. 2017; 168: 584-599Abstract Full Text Full Text PDF PubMed Scopus (250) Google J.M. E. A. M. N. M. E. S. E. The the use of PubMed Scopus Google Scholar and the the use of a single all-inclusive DNA test is a more for molecular we report orthogonal validation of WGS fresh-frozen biopsies and to for the the of WGS using with tumor is to the of routinely used diagnostic with technical of we a single test can the small variants and routinely detected by targeted gene fusion and tumor The has toward a clinically of a processing of sample and DNA and data analysis and report Currently, WGS a tumor is approaches for WGS to for is to a sequencing by WGS and with is WGS with become for samples in the The to using WGS in is the need of samples as for most an in the are The of WGS in is in a clinical validation E. I. E. K. whole genome sequencing in standard diagnostics for cancer 2020; PubMed Scopus Google Scholar The high of WGS is the of are from most diagnostics for the use of fresh-frozen tumor high-quality DNA and sequencing processing of the blood sample to as a for the tumor all variants can be and can be a of J. Lolkema M.P. N. E. C. K. S. A. M. M. S. E. of metastatic PubMed Scopus Google Scholar the of all variants in the tumor are in clinical and a is for WGS in for S. K. S. M. M. M. E. M. Personalized for cancer mutation and PubMed Scopus Google M. R. J. A. A. J. Robson K. K. M. detection of variants by a clinical diagnostic for tumor molecular and cancer 2017; PubMed Scopus Google Scholar of variants using of toward and and the is large and somatic variants be and are for assay. the whole genome data and become and for the and a between can be detected and be To the WGS all variants J. Lolkema M.P. N. E. C. K. S. A. M. M. S. E. of metastatic PubMed Scopus Google Scholar for a the all variants of gene the is used as a to number to whole of the DNA in and number by of A. K. K. R. R. M. to and clinically relevant variants using molecular Cancer PubMed Scopus Google Scholar J. R. J. a precision Oncol. 2017; Scopus Google Scholar and C. J. M.P. A. A. I. J. J. J. C. Dienstmann R. A. N. Cancer genome the and clinical of tumor PubMed Scopus Google for with clinical clinical is in the using a national clinical study last accessed DNA sequencing are as and the technical validation and are by national and can have and for the of F. Remon J. Mateo J. Westphalen C.B. Barlesi F. Lolkema M.P. Normanno N. Scarpa A. Robson M. Meric-Bernstam F. Wagle N. Stenzinger A. Bonastre J. Bayle A. Michiels S. Bièche I. Rouleau E. Jezdic S. Douillard J.-Y. Reis-Filho J. Dienstmann R. André F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.Ann Oncol. 2020; 31: 1491-1505Abstract Full Text Full Text PDF PubMed Scopus (119) Google I. E. A. S. M. M. A. K. J. Normanno N. Rouleau E. E. E. of of next-generation sequencing in clinical diagnostic molecular for analysis of an of 2017; PubMed Scopus Google C. S. J. for validation of next-generation a of the for and of 2017; Full Text Full Text PDF PubMed Scopus Google S. C. A. A. M. C. and for next-generation sequencing a of the for and the of Full Text Full Text PDF PubMed Scopus Google and for validation we have the for and validation of sequencing in in the with the of assays by the and last accessed and the for in diagnostic diagnostics in and the of the of the and of the of in diagnostic and and 2017; Scholar is genome sequencing become and as by with be a of With the in sequencing the has become for a analysis and of the sequencing data of WGS for the have most the and has become the and the data to all are of the analysis and meet the of in diagnostics and diagnostic of the are of a diagnostic validation for can be is by in of to with developments in the need to be and by a to diagnostic With the of more targeted drugs and biomarkers, in to of the test is to be to and to the clinical and and WGS a and of diagnostic DNA an of the and the need of and test developments of the validation In the data from patients in and from the be for the of the biomarkers and of the can be F. S. C. C. F. a of in clinical in Genet. PubMed Scopus Google Scholar In to the WGS with the use of the blood sample as a the of the the is to of of all variants are in the to of a loss of in the of all the of to report can be the of the tumor the clinical context and of the In analysis of all DNA be to a of molecular tumor a gene fusion is in and for a fusion be and be a the of DNA as in gene N. genome in have next-generation sequencing PubMed Scopus Google Scholar In analysis of the using whole sequencing in to WGS can a molecular of a DNA can in a and of tumor Currently, tumor has to using in the context of cancer and with J. J. E. J. A. J. C. S. C. M. analysis using and to tumor Oncol. PubMed Scopus Google R. E. A. J. C. Lolkema M.P. N. and Working and metastatic using mutation 2020; PubMed Scopus Google Scholar can a in WGS of the to a the WGS can have for clinical use and for clinical study a of the tumor a of data and the to in and to the to targeted greatly of cancer and the of identified biomarkers, targeted and for and for with data and for and for sample The data from and the Center of Cancer Treatment and of of and the and the whole genome sequencing and and validated and the all and of the